Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OCUL Ocular Therapeutix	$9.36 -1.1%	$8.19	$5.79 ▼ $11.78	$1.53B	1.43	1.41 million shs	1.16 million shs
OGN Organon & Co.	$10.08 -0.7%	$9.61	$8.01 ▼ $23.10	$2.59B	0.6	3.54 million shs	2.38 million shs
PTCT PTC Therapeutics	$48.77 -0.8%	$48.21	$29.02 ▼ $58.38	$3.89B	0.5	862,349 shs	307,079 shs
RYTM Rhythm Pharmaceuticals	$65.78 -1.7%	$62.86	$40.46 ▼ $69.89	$4.18B	2.26	557,108 shs	628,374 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OCUL Ocular Therapeutix	0.00%	+1.52%	+11.69%	+47.17%	+39.91%
OGN Organon & Co.	0.00%	+2.09%	+5.61%	-22.71%	-50.42%
PTCT PTC Therapeutics	0.00%	-2.14%	-4.61%	+12.79%	+57.33%
RYTM Rhythm Pharmaceuticals	0.00%	+4.85%	+2.15%	+40.10%	+61.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OCUL Ocular Therapeutix	3.9446 of 5 stars	3.5	1.0	0.0	4.1	2.7	2.5	0.0
OGN Organon & Co.	4.8936 of 5 stars	3.3	4.0	1.7	3.7	1.7	3.3	2.5
PTCT PTC Therapeutics	4.316 of 5 stars	4.3	1.0	0.0	4.4	1.4	0.8	1.3
RYTM Rhythm Pharmaceuticals	3.8182 of 5 stars	3.5	2.0	0.0	4.3	1.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OCUL Ocular Therapeutix	3.00	Buy	$17.33	85.19% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	78.66% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	33.28% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$77.31	17.53% Upside

Current Analyst Ratings Breakdown

Latest OCUL, RYTM, PTCT, and OGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$84.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/9/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$55.00 ➝ $68.00
5/8/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/7/2025	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$57.00 ➝ $58.00
5/7/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$70.00 ➝ $66.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OCUL Ocular Therapeutix	$63.72M	23.40	N/A	N/A	$2.01 per share	4.66
OGN Organon & Co.	$6.40B	0.41	$4.99 per share	2.02	$1.83 per share	5.51
PTCT PTC Therapeutics	$806.78M	4.79	N/A	N/A	($14.24) per share	-3.42
RYTM Rhythm Pharmaceuticals	$130.13M	32.16	N/A	N/A	$0.35 per share	187.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.50	2.69	1.04	11.92%	227.43%	7.34%	8/5/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.49	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)

Latest OCUL, RYTM, PTCT, and OGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.79%	N/A	2.78%	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest OCUL, RYTM, PTCT, and OGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OCUL Ocular Therapeutix	0.26	10.22	10.14
OGN Organon & Co.	16.49	1.67	1.15
PTCT PTC Therapeutics	N/A	3.89	3.85
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OCUL Ocular Therapeutix	59.21%
OGN Organon & Co.	77.43%
PTCT PTC Therapeutics	N/A
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
OCUL Ocular Therapeutix	2.30%
OGN Organon & Co.	1.96%
PTCT PTC Therapeutics	5.50%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable

OCUL, RYTM, PTCT, and OGN Headlines

Recent News About These Companies

Cardiac Rhythm Remote Monitoring Devices Market Grows to USD 8.8B by 2035, CAGR at 5.3%

July 4 at 1:07 PM | pharmiweb.comP

NPSL: Bristol Rhythm's halftime lead, playoff hopes vanish in 6-3 loss to Charlottetowne Hops

July 4 at 1:07 PM | heraldcourier.comH

Call Super Unveils Mix CD for Dekmantel, ‘A Rhythm Protects One’

July 4 at 1:07 PM | thequietus.comT

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 1,319 Shares of Stock

July 4 at 8:08 AM | insidertrades.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Alastair Garfield Sells 1,319 Shares

July 3 at 6:41 PM | marketbeat.com

Rhythm Pharmaceuticals Inc News (RYTM) - Investing.com

July 2 at 7:27 PM | investing.com

Adcock, Chiefs blank Rhythm to win 5th straight

July 1, 2025 | wpsdlocal6.comW

NPSL: Bristol Rhythm fall on the road, close out season with two home games this week

June 30, 2025 | heraldcourier.comH

The UniverSoul Circus brings its 'Rhythm of the World' tour to National Harbor

June 30, 2025 | wusa9.comW

Of Wood, Worship And Wonder: Rhythm Wagholikar On The Rath Yatra Tradition

June 28, 2025 | msn.com

Rhythm & Food community BBQ

June 28, 2025 | kxnet.comK

Rhythm & Roots unveils artist schedule, puts single-day tickets on sale

June 28, 2025 | heraldcourier.comH

Rhythm & Rally offer pickleball for Neurodivergent kids

June 28, 2025 | 41nbc.com4

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Market Outperform Rating from JMP Securities

June 28, 2025 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (RYTM) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Rhythm Pharmaceuticals: Growth Is Expected To Go Parabolic

June 27, 2025 | seekingalpha.com

Rhythm and Blues Show

June 27, 2025 | deltanews.tvD

Rhythm Pharmaceuticals Announces Late-Breaking Abstracts for ENDO 2025 Featuring Pivotal Phase 3 and Phase 2 Trial Results on Acquired Hypothalamic Obesity - Nasdaq

June 27, 2025 | nasdaq.com

Rhythm Pharmaceuticals' (RYTM) "Market Outperform" Rating Reiterated at JMP Securities

June 26, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

June 25, 2025 | finanznachrichten.de

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

June 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, RYTM, PTCT, and OGN Company Descriptions

Ocular Therapeutix NASDAQ:OCUL

$9.36 -0.10 (-1.06%)

Closing price 07/3/2025 01:45 PM Eastern

Extended Trading

$9.62 +0.26 (+2.78%)

As of 07/3/2025 04:49 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Organon & Co. NYSE:OGN

$10.07 -0.08 (-0.74%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$10.06 -0.02 (-0.20%)

As of 07/3/2025 04:48 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

PTC Therapeutics NASDAQ:PTCT

$48.77 -0.38 (-0.77%)

Closing price 07/3/2025 03:28 PM Eastern

Extended Trading

$48.77 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Rhythm Pharmaceuticals NASDAQ:RYTM

$65.78 -1.15 (-1.71%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$65.74 -0.04 (-0.06%)

As of 07/3/2025 04:20 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time